Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirvetuximab Soravtansine + Pembrolizumab in MSS Endometrial Cancer
NCT03835819Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2020
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mirvetuximab soravtansine and pembrolizumab in endometrial cancer (EC), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Objective Response Rate at 6 months and Progression-Free Survival at 6 Months. Started Jan 2020; status: active, not recruiting.
02
Drugs
mirvetuximab soravtansinepembrolizumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03835819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03835819.